mTORC1 hyperactivation in lymphangioleiomyomatosis leads to <i>ACE2</i> upregulation in type II pneumocytes: implications for COVID-19.

Tang, Yan; Kwiatkowski, David J; Henske, Elizabeth P

mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19.

Tang, Yan; Kwiatkowski, David J; Henske, Elizabeth P.

Tang Y; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Kwiatkowski DJ; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Henske EP; D.J. Kwiatkowski and E.P. Henske contributed equally to this article as lead authors and supervised the work.

Eur Respir J ; 57(2)2021 02.

Article in English | MEDLINE | ID: covidwho-1084202

Subject(s)

Alveolar Epithelial Cells; Angiotensin-Converting Enzyme 2/genetics; COVID-19; Lymphangioleiomyomatosis; Mechanistic Target of Rapamycin Complex 1/metabolism; Sirolimus/pharmacology; Alveolar Epithelial Cells/metabolism; Alveolar Epithelial Cells/pathology; Antibiotics, Antineoplastic/pharmacology; COVID-19/metabolism; COVID-19/virology; Cancer-Associated Fibroblasts/metabolism; Humans; Interferons/metabolism; Interleukin-6/metabolism; Lymphangioleiomyomatosis/metabolism; Lymphangioleiomyomatosis/pathology; SARS-CoV-2/physiology; Signal Transduction/drug effects; Up-Regulation/drug effects

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Lymphangioleiomyomatosis / Sirolimus / Alveolar Epithelial Cells / Mechanistic Target of Rapamycin Complex 1 / Angiotensin-Converting Enzyme 2 / COVID-19 Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: 13993003.02737-2020

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google